Axplora is repositioning its Italian Farmabios site on high-potency APIs as UDCA production moves to its FDA-approved Vizag facility in India, consolidating supply and scaling for global demand.
$60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy.
Axplora to expand its Farmabios site in Gropello Cairoli, Italy, with a €35 million investment.
Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for the first line of its new production unit at Gropello Cairoli, Italy, expanding its large scale manufacturing capabilities for high potent active pharmaceutical ingredients (HPAPIs) and steroids.
Interview with Sylke Hassel, previous CEO of PharmaZell and current CEO of Axplora following the merger with Novasep.
